<DOC>
	<DOCNO>NCT01827072</DOCNO>
	<brief_summary>Patients diagnose Multifocal Motor Neuropathy confirm base European Federation Neurological Societies/ Peripheral . Nerve Society Guideline . Patients meet inclusion criterion conflict exclusion criterion receive NPB-01 ( intravenous immunoglobulin ) 400mg/kg/day five consecutive day . Subsequently , patient receive NPB-01 1g/kg every 3weeks evaluate Medical Research Council（MRC） score Guy 's Neurological Disability Scale（GNDS） et al . As safety endpoint , safety NPB-01 investigate occurrence adverse event one year start study treatment .</brief_summary>
	<brief_title>Phase III Clinical Trial NPB-01maintenance Therapy Patients With Multifocal Motor Neuropathy .</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Neuritis</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>1 . Patients need highdose intravenous immunoglobulin（greater equal 1g/kg） therapy . 2 . Patients continue treatment MMN without addition increase 30 day inform consent . 3 . Patients MRC score increase 1 stage great equal 2 muscle decrease relative muscle highdose intravenous immunoglobulin therapy . 4 . Patients great equal twenty year old informed consent . 1 . Patients treat Plasmapheresis 3 month inform consent . 2 . Patients treat Rituximab Natalizumab 6 month inform consent . 3 . Patients treat Interferonbeta 6 month inform consent . 4 . Patients treat highdose intravenous immunoglobulin（greater equal 1g/kg） 8 week inform consent . 5 . Patients treat intravenous immunoglobulin 3 week inform consent . 6 . Patients history shock hypersensitivity NPB01 . 7 . Patients IgA deficiency . 8 . Patients malignancy . 9 . Patients impaired liver function . 10 . Patients impaired renal function . 11 . Patients cerebro cardiovascular disorder . 12 . Patients high risk thromboembolism . 13 . Patients hemolytic/hemorrhagic anemia . 14 . Patients decrease cardiac function . 15 . Patients decreased platelet .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>IVIG Multifocal Motor Neuropathy</keyword>
	<keyword>Patients Multifocal Motor Neuropathy</keyword>
</DOC>